Show simple item record

dc.contributor.authorParkes, EE
dc.contributor.authorHumphries, MP
dc.contributor.authorGilmore, E
dc.contributor.authorSidi, FA
dc.contributor.authorBingham, V
dc.contributor.authorPhyu, SM
dc.contributor.authorCraig, S
dc.contributor.authorGraham, C
dc.contributor.authorMiller, J
dc.contributor.authorGriffin, D
dc.contributor.authorSalto-Tellez, M
dc.contributor.authorMadden, SF
dc.contributor.authorKennedy, RD
dc.contributor.authorBakhoum, SF
dc.contributor.authorMcQuaid, S
dc.contributor.authorBuckley, NE
dc.date.accessioned2021-07-26T08:19:35Z
dc.date.available2021-07-26T08:19:35Z
dc.date.issued2021-06-25
dc.identifier.citationNPJ breast cancer, 2021, 7 (1), pp. 81 - ?
dc.identifier.issn2374-4677
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4689
dc.identifier.eissn2374-4677
dc.identifier.eissn2374-4677
dc.identifier.eissn2374-4677
dc.identifier.eissn2374-4677en_US
dc.identifier.doi10.1038/s41523-021-00283-z
dc.identifier.doi10.1038/s41523-021-00283-z
dc.identifier.doi10.1038/s41523-021-00283-z
dc.identifier.doi10.1038/s41523-021-00283-zen_US
dc.description.abstractSTING signaling in cancer is a crucial component of response to immunotherapy and other anti-cancer treatments. Currently, there is no robust method of measuring STING activation in cancer. Here, we describe an immunohistochemistry-based assay with digital pathology assessment of STING in tumor cells. Using this novel approach in estrogen receptor-positive (ER+) and ER- breast cancer, we identify perinuclear-localized expression of STING (pnSTING) in ER+ cases as an independent predictor of good prognosis, associated with immune cell infiltration and upregulation of immune checkpoints. Tumors with low pnSTING are immunosuppressed with increased infiltration of "M2"-polarized macrophages. In ER- disease, pnSTING does not appear to have a significant prognostic role with STING uncoupled from interferon responses. Importantly, a gene signature defining low pnSTING expression is predictive of poor prognosis in independent ER+ datasets. Low pnSTING is associated with chromosomal instability, MYC amplification and mTOR signaling, suggesting novel therapeutic approaches for this subgroup.
dc.formatElectronic
dc.format.extent81 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleThe clinical and molecular significance associated with STING signaling in breast cancer.
dc.typeJournal Article
dcterms.dateAccepted2021-05-27
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1038/s41523-021-00283-z
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-06-25
rioxxterms.licenseref.startdate2021-06-25en_US
dc.relation.isPartOfNPJ breast cancer
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Integrated Pathology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/ImmNet
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Integrated Pathology
pubs.publication-statusPublished
pubs.volume7en_US
pubs.embargo.termsNot known
icr.researchteamIntegrated Pathology
icr.researchteamIntegrated Pathologyen_US
dc.contributor.icrauthorSalto-Tellez, Manuelen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/